👶Pregnancy
Human outcome data exist, but there are still meaningful concerns: stimulants can cause vasoconstriction and may reduce placental perfusion. Use during pregnancy may be associated with risks like low birth weight or premature birth, and newborns may show withdrawal-like symptoms (agitation, irritability, feeding issues, excessive drowsiness). Nonpharmacologic options are preferred for mild-to-moderate ADHD during pregnancy. If medication is used, shared decision-making matters: lowest effective dose, simplest regimen, and careful monitoring.🤱Breastfeeding
Amphetamine and dextroamphetamine pass into breast milk. Reported relative infant dose ranges are variable, and manufacturers generally do not recommend breastfeeding due to potential infant risks (blood pressure/heart rate effects, irritability, poor feeding, sleep disruption, growth concerns). If treatment is considered essential, risk-benefit decisions should be individualized with infant monitoring for feeding difficulties, irritability, and insomnia.👧Children & Adolescents (Under 18)
Extended-release stimulants: Not recommended for children younger than 6 years because younger kids can have higher plasma exposure and higher rates of adverse reactions, including clinically significant weight loss. If a child <6 is experiencing weight loss or other adverse effects on an extended-release stimulant, clinicians should consider stopping and/or switching to an alternative (like an immediate-release formulation). For all pediatric patients, growth (height/weight), appetite, sleep, and behavior need routine tracking.👴Older Adults (65+)
Refer to adult dosing but start low and go slow. Older adults may be more sensitive to blood pressure/heart rate effects, insomnia, and appetite/weight changes. Cardiac screening and BP/HR monitoring become especially important.🔬Liver Impairment
No formal manufacturer dose adjustments are provided, but use caution; reduced elimination can increase exposure and side effects.💧Kidney Impairment
Use caution. For certain extended-release products, severe renal impairment requires lower dosing limits and end-stage renal disease may make use not recommended.